Affinity Asset Advisors LLC Invests $3.03 Million in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Affinity Asset Advisors LLC bought a new stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the second quarter, HoldingsChannel reports. The firm bought 650,000 shares of the company’s stock, valued at approximately $3,029,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bellevue Group AG boosted its holdings in shares of Black Diamond Therapeutics by 4.9% during the 4th quarter. Bellevue Group AG now owns 8,535,839 shares of the company’s stock valued at $23,986,000 after buying an additional 400,000 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in Black Diamond Therapeutics during the second quarter worth about $3,891,000. TD Asset Management Inc grew its holdings in Black Diamond Therapeutics by 275.9% in the second quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock worth $1,241,000 after purchasing an additional 195,464 shares during the period. Renaissance Technologies LLC increased its stake in shares of Black Diamond Therapeutics by 24.1% during the second quarter. Renaissance Technologies LLC now owns 263,900 shares of the company’s stock valued at $1,230,000 after purchasing an additional 51,300 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Black Diamond Therapeutics by 79.1% during the second quarter. Dimensional Fund Advisors LP now owns 200,044 shares of the company’s stock valued at $932,000 after purchasing an additional 88,378 shares during the last quarter. 95.47% of the stock is owned by hedge funds and other institutional investors.

Black Diamond Therapeutics Price Performance

Black Diamond Therapeutics stock opened at $4.58 on Wednesday. Black Diamond Therapeutics, Inc. has a 12 month low of $1.62 and a 12 month high of $7.66. The stock has a fifty day simple moving average of $5.63 and a two-hundred day simple moving average of $5.36.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Analysts expect that Black Diamond Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a research report on Tuesday. Raymond James assumed coverage on Black Diamond Therapeutics in a research report on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 price target for the company. Piper Sandler increased their price objective on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Wedbush restated an “outperform” rating and set a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Tuesday, September 10th.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.